$0.64
12.32% today
Nasdaq, Dec 24, 10:10 pm CET
ISIN
US4831191030
Symbol
KALA

Kala Pharmaceuticals, Inc. Stock price

$0.64
+0.02 3.76% 1M
-3.36 84.00% 6M
-6.30 90.78% YTD
-5.60 89.74% 1Y
-3.24 83.50% 3Y
-381.98 99.83% 5Y
-922.94 99.93% 10Y
-922.94 99.93% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.07 12.32%
ISIN
US4831191030
Symbol
KALA
Industry

Key metrics

Basic
Market capitalization
$6.1m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
22.2%
Return on Equity
-316.3%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-36.7m | -
EBIT
$-37.0m | $-41.4m
Net Income
$-35.8m | -
Free Cash Flow
$-32.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
10.5% | -
EBIT
10.3% | -1.0%
Net Income
8.5% | -
Free Cash Flow
1.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-5.1
FCF per Share
-
Short interest
26.1%
Employees
38
Rev per Employee
$0.0
Show more

Is Kala Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Kala Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Kala Pharmaceuticals, Inc. forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Kala Pharmaceuticals, Inc. forecast:

Hold
57%
Sell
43%

Financial data from Kala Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
4% 4%
-
- Research and Development Expense 24 24
10% 10%
-
-37 -37
11% 11%
-
- Depreciation and Amortization 0.33 0.33
27% 27%
-
EBIT (Operating Income) EBIT -37 -37
10% 10%
-
Net Profit -36 -36
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kala Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kala Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering...
Negative
24/7 Wall Street
3 months ago
Always be cautious before investing in a penny stock. While some will turn out to be explosive winners, like Advanced Micro Devices, others turn out to be expensive duds.
Neutral
The Motley Fool
5 months ago
Kala Bio (KALA -2.19%), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 (GAAP).
More Kala Pharmaceuticals, Inc. News

Company Profile

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.

Head office United States
CEO Todd Bazemore
Employees 38
Founded 2009
Website www.kalarx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today